Follow the 바디텍메드 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 바디텍메드 has recorded 21 public disclosures. Market capitalisation: €243.8bn. The latest transaction was disclosed on 7 April 2026 (Other). Among the most active insiders: 박대균. Every trade is openly available.
21
Insider Decl.
n/a
Thresholds
n/a
2 ops.
Buy Volume
n/a
2 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,497 of 28,134 companies
69.4
score / 100
Value
63
Quality
76
FCF yld-4.9%
Earn yld9.7%
EV/EBITDA6.8x
ROE11%
Gross mgn59%
Net mgn15%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Bodytechmed is a healthcare and pharmaceutical company focused on the development of in vitro diagnostic devices. The company is listed on the XKRX market.